Ann: Annual Report to shareholders, page-2

"It has been a year of solid growth and your Company has once again worked tirelessly throughout the year to deliver
remarkable progress across our deep clinical pipeline.
Despite the challenges that the broader biotechnology sector has continued to face, we are steadfast in the view
that Imugene is positioned more strongly than ever before, and in time the Company and shareholders will see the
benefits.The Board and management recognise the impact of the falling share price and understand the concerns
expressed by shareholders.

In closing, I also want to extend my thanks to our shareholders for your support of Imugene. The share price
performance is disappointing, but moving into 2024, I am confident that we are better positioned than ever before to
overcome challenges, and pave the way for a bright future for Imugene."


At least he noticed. But using solid growth ( pipeline ) and falling share price in one paragraph, mmh.

Let's hope 2024 will be better, 2023 is already ...ucked up. Don't think the CF33 peer review will change much as the market has been informed indirectly several times that the virus works as expected.

Change of tune here:

Given the breadth of programs Imugene now possesses, management continues to pursue out-licensing opportunities
for its B-cell immunotherapies. Mmh, did they really do something here or did Ben get them finally moving.


GLTA